Studies

Crohn’s Disease (CD) and Ulcerative Colitis (UC) are collectively known as Inflammatory Bowel Disease (IBD) and a small number of patients are diagnosed with IBD-Undetermined, where a distinction between the two conditions is not possible. They are both chronic relapsing-remitting diseases of the gastrointestinal tract, with peak age of onset Read more…

HARP-X is a prospective multi-centre, open label induction and randomized maintenance pilot study of Tofacitinib in subjects with chronic, antibiotic refractory or dependent pouchitis. The primary objective is to determine the effect of tofacitinib maintenance therapy on endoscopic response in subjects with active, chronic, antibiotic dependent or refractory pouchitis. Background Read more…

VARIATION was a prospective multi-centre Irish study aiming to determine the impact of IBD and various medications for treatment of IBD on antibody responses to vaccination against COVID-19. Background and aims: Evidence suggests patients with inflammatory bowel disease [IBD] receiving TNF antagonists have attenuated response to vaccination against COVID-19. We sought Read more…

Abnormal colonization of the gastrointestinal tract by Enterobacteriaceae might play a role in the development of Crohn’s Disease (CD). Clearance of this bacteria could represent a new therapeutic strategy in CD. The purpose of this study was to develop a non-invasive test to look for a specific bacteria, invasive Escherichia Read more…

SECURE-IBD is an international, pediatric and adult database to monitor and report on outcomes of COVID-19 occurring in IBD patients. With the collaboration of our entire IBD community, we will rapidly be able to define the impact of COVID-19 on patients with IBD and how factors such as age, comorbidities, Read more…

STEIG is a retrospective study of clinical outcomes of off licence treatment with Ustekinumab for Crohn’s Disease. Ustekinumab (Stelara) is a monoclonal antibody against the common p40 subunit of IL-12 and IL-23 and has recently been approved for (intravenous) induction and (subcutaneous) maintenance treatment of patients with moderately-to-severely active Crohn’s disease Read more…

I-CARE is the first observational European prospective cohort study that will provide unique information (safety, efficacy, risk-benefit ratio, and healthcare costs) on the long-term use of recommended therapy in IBD, using a predefined standardized follow-up. These real world data will be used to guide clinicians as well as Healthcare authorities to provide the best care for IBD patients Read more…

GOAL-ARC is a nationwide multi-centred investigator initiated randomized control trial to evaluate the use of personalized Golimumab (GLM) dose adjustment in ulcerative colitis. The primary objective is to ascertain if dose adjustment of GLM, based on GLM drug levels and FCP levels, results in higher response and remission rates than Read more…